Full history for every metric is available with a Kvantra account
Forward Pharma A/S (FWP)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 1,250 | 0 | 0 | 0 | -0 | -0 |
| Operating profit | $m | -4 | 7 | |||||
| Net profit | $m | -33 | 917 | -9 | -4 | -6 | 0 | - |
| EPS reported | $ | 0.00 | - | |||||
| Operating cashflow per share | $ | -0.02 | -0.02 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.02 | -0.02 | |||||
| Free cash flow | $m | -2 | 12 | |||||
| Net debt | $m | -71 | -65 | |||||
| Book value equity | $m | 71 | 62 | |||||
| Book value per share | $ | 0.72 | 0.64 | |||||
| Number of shares | m | 97.76 | 96.88 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 8.24 | 2.69 | |||||
| P/S LTM | x | -3,104.46 | 0.00 | |||||
| P/FCF LTM | x | -247.41 | 0.00 | |||||
| EV/EBITDA LTM | x | -271.07 | 37.40 | |||||
| EV/Sales LTM | x | -2,728.03 | 376.44 | |||||
| Earnings Yield LTM | % | 0.02% | 0.05% | |||||
| FCF Yield | % | -0.40% | - | |||||
| Quality | ||||||||
| ROE | % | 0.13% | 0.12% | |||||
| ROIC | % | 0.26% | 0.26% | |||||
| Operating margin | % | 2060.6% | 2060.6% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | 1254.8% | 1254.8% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 37.40 | 37.40 | |||||
| EBIT/Net interest | x | 1.95 | 1.95 | |||||
| Net debt/market cap | % | -12.13% | - | |||||
| Net debt/Equity | x | -1.00 | -1.05 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Forward Pharma A/S currently conducts no significant business activities. In its prior operations, the company functioned as a biopharmaceutical firm. It dedicated its efforts to advancing FP187, its exclusive formulation of dimethyl fumarate, designed to address inflammatory and neurological disorders. Forward Pharma A/S was founded in 2005 and maintains its corporate headquarters in Copenhagen, Denmark.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Forward Pharma A/S (FWP)
Forward Pharma A/S currently conducts no significant business activities. In its prior operations, the company functioned as a biopharmaceutical firm. It dedicated its efforts to advancing FP187, its exclusive formulation of dimethyl fumarate, designed to address inflammatory and neurological disorders. Forward Pharma A/S was founded in 2005 and maintains its corporate headquarters in Copenhagen, Denmark.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free